EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access · CC BY 4.0

Is it time to retire bolus cisplatin? Lessons from the ConCERT trial

Ross D Merkin, Aarti Bhatia iD

JNCI: Journal of the National Cancer Institute · 01.11.2026 · 118 (11) · 2001-2003

DOI: 10.1093/jnci/djag331 ↗

Kurz gefasst

Editorial in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 14.10.2026. Verfasst von Ross D Merkin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute, Boston, MA, United States. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Mass General Brigham Cancer Institute, Boston, MA, United States.
  • Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
  • Massachusetts Eye and Ear, Boston, MA, United States.
  • Department of Medicine, Harvard Medical School, Boston, MA, United States.
  • Department of Internal Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.

ORCID-Profile: Aarti Bhatia

Zitieren

APA

Merkin, R. D., & Bhatia, A. (2026). Is it time to retire bolus cisplatin? Lessons from the ConCERT trial. JNCI: Journal of the National Cancer Institute, 118(11), 2001-2003. https://doi.org/10.1093/jnci/djag331

Vancouver

Merkin RD, Bhatia A. Is it time to retire bolus cisplatin? Lessons from the ConCERT trial. JNCI: Journal of the National Cancer Institute. 2026;118(11):2001-2003. doi:10.1093/jnci/djag331

BibTeX
@article{Merkin2026,
  author = {Merkin, Ross D and Bhatia, Aarti},
  title = {Is it time to retire bolus cisplatin? Lessons from the ConCERT trial},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {11},
  pages = {2001--2003},
  doi = {10.1093/jnci/djag331}
}
Kostenlos starten →